Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the safety and efficacy of PDT at 30% verteporfin dose in the treatment of CSC.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 50% dose PDT | Active Comparator | patients in this group was given 50% verteporfin dose PDT |
|
| 30% dose PDT | Experimental | patients in this group was given 30% verteporfin dose PDT |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PDT | Procedure | 30% or 50% verteporfin dose PDT was given to patients with CSC |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in BCVA | 1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Leakage at RPE level in FA | 1 week | |
| Change from baseline in central retinal thickness | 1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year | |
| The incidence rate of adverse event |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mingwei Zhao, M.D | Peking University People's Hospital | Study Director |
| Youxin Chen, M.D | Peking Union Medical College | Principal Investigator |
| Feng Zhang, M.D | Beijing Tongren Hospital of Capital Medical University | Principal Investigator |
| Hong Dai, M.D | Beijing Hospital | Principal Investigator |
| Xiaoxin Li, M.D | Peking University People's Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| People's Hospital of Peking University | Beijing | Beijing Municipality | 100044 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40522203 | Derived | Lange CA, Qureshi R, Pauleikhoff L. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3. | |
| 25555191 | Derived | Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, Kang X, Liu Y, Yang L, Li Y, Zhou P, Pan CT, Zhang L, Liu P, Zhou H, Jiao X, Xiong Y, Tian R, Lu Y, Yu X, Li X. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015 Mar;133(3):333-40. doi: 10.1001/jamaophthalmol.2014.5312. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D056833 | Central Serous Chorioretinopathy |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C008848 | 1-phenyl-3,3-dimethyltriazene |
| D010778 | Photochemotherapy |
| ID | Term |
|---|---|
| D003131 | Combined Modality Therapy |
| D013812 | Therapeutics |
| D004358 | Drug Therapy |
| D010789 | Phototherapy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year |